D Liénard Selected Research

D Liénard Research Topics

16	Neoplasms (Cancer) 02/2004 - 01/2000
14	Melanoma (Melanoma, Malignant) 02/2004 - 01/2000
2	Sarcoma (Soft Tissue Sarcoma) 10/2001 - 11/2000
2	Testicular Neoplasms (Testicular Cancer) 03/2001 - 08/2000
1	Lymphatic Metastasis 02/2004
1	Neoplasm Metastasis (Metastasis) 07/2002
1	Human Influenza (Influenza) 06/2001
1	Virus Diseases (Viral Diseases) 03/2001
1	Necrosis 11/2000
1	Vaccinia 01/2000

10	Peptides (Polypeptides)IBA 12/2001 - 01/2000
6	MART-1 AntigenIBA 12/2001 - 01/2000
5	VaccinesIBA 09/2001 - 03/2001
5	AntigensIBA 08/2001 - 08/2000
3	Neoplasm Antigens (Tumor Antigens)IBA 07/2001 - 03/2001
2	Interferon-gamma (Interferon, gamma)IBA 02/2004 - 11/2000
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2001 - 11/2000
2	Melphalan (Alkeran)FDA LinkGeneric 10/2001 - 11/2000
2	HLA-A*02:01 antigenIBA 09/2001 - 03/2001
2	HLA-A2 Antigen (HLA A2 Antigen)IBA 03/2001 - 01/2001
2	Cancer VaccinesIBA 01/2001 - 08/2000
2	EpitopesIBA 01/2001 - 07/2000
1	Interferon alpha-2 (Roferon-A)FDA Link 02/2004
1	viscum album peptide (Iscador)IBA 02/2004
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2002
1	Cisplatin (Platino)FDA LinkGeneric 07/2002
1	Interleukin-2 (IL2)IBA 07/2002
1	CytokinesIBA 07/2002
1	Interferon-alpha (Interferon Alfa)IBA 07/2002
1	Pharmaceutical PreparationsIBA 10/2001
1	Antineoplastic Agents (Antineoplastics)IBA 10/2001
1	Telomerase (Telomerase Reverse Transcriptase)IBA 09/2001
1	RibonucleoproteinsIBA 09/2001
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2001
1	peptide NY-ESO-1 157-165IBA 03/2001
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 03/2001
1	Complementary DNA (cDNA)IBA 08/2000
1	NucleotidesIBA 01/2000

3	Immunotherapy 09/2001 - 01/2000
2	Neoadjuvant Therapy 10/2001 - 11/2000
1	Limb Salvage 11/2000
1	Surgical Amputation (Amputations) 11/2000
1	Disarticulation 11/2000
1	Drug Therapy (Chemotherapy) 11/2000